EP 3683311 A1 20200722 - CANCER TREATMENT DRUG
Title (en)
CANCER TREATMENT DRUG
Title (de)
ARZNEIMITTEL ZUR KREBSBEHANDLUNG
Title (fr)
MÉDICAMENT POUR LE TRAITEMENT DU CANCER
Publication
Application
Priority
- JP 2017174125 A 20170911
- JP 2018033502 W 20180910
Abstract (en)
The present invention provides: a peptide that includes a partial amino acid sequence of the C16orf74 protein, includes the cysteine at position 7 and/or the cysteine at position 14 of the C16orf74 protein, and inhibits dimer formation of the C16orf74 protein; a pharmaceutical composition for cancer treatment that includes the peptide; and a screening method for cancer treatment drugs that takes as the indicator inhibition of dimer formation of the C16orf74 protein.
IPC 8 full level
C12N 15/12 (2006.01); A61K 35/76 (2015.01); A61K 38/17 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 1/18 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 19/00 (2006.01); C12Q 1/02 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01)
CPC (source: EP US)
A61K 35/76 (2013.01 - EP); A61K 38/17 (2013.01 - EP); A61K 45/00 (2013.01 - EP); A61K 48/00 (2013.01 - EP); A61P 1/18 (2017.12 - EP); A61P 35/00 (2017.12 - EP US); A61P 43/00 (2017.12 - EP); C07K 7/08 (2013.01 - EP US); C07K 14/47 (2013.01 - EP); C07K 19/00 (2013.01 - EP); C12Q 1/02 (2013.01 - EP); G01N 33/15 (2013.01 - EP); G01N 33/50 (2013.01 - EP); A61K 9/0019 (2013.01 - US); A61K 38/00 (2013.01 - US); C07K 2319/00 (2013.01 - EP); C07K 2319/03 (2013.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
EP 3683311 A1 20200722; EP 3683311 A4 20210602; CN 111566213 A 20200821; CN 111566213 B 20230804; JP 2023083423 A 20230615; JP 7320840 B2 20230804; JP WO2019050036 A1 20210114; US 11203615 B2 20211221; US 2020270308 A1 20200827; WO 2019050036 A1 20190314
DOCDB simple family (application)
EP 18855070 A 20180910; CN 201880072474 A 20180910; JP 2018033502 W 20180910; JP 2019541049 A 20180910; JP 2023067718 A 20230418; US 201816645859 A 20180910